(NASDAQ)
3.04
-0.1500   (-4.70%)
After Hours: 3.03 -0.0100 (-0.33%)
Volume (24h) Market Cap. Day Range 52w Range
111.73K 272.06M 3.00 - 3.22 0.63 - 12.17
Feb-26-21 02:00AM Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money ReportGlobeNewswire
Feb-18-21 07:00AM ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent DirectorGlobeNewswire
Feb-16-21 10:02AM Tiziana Life Sciences to Present at the BIO CEO & Investor Digital ConferenceGlobeNewswire
Feb-05-21 02:00AM Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of DirectorGlobeNewswire
Feb-03-21 10:11AM Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 AntibodyZacks
02:00AM Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive InterviewGlobeNewswire
Feb-02-21 05:55AM Tiziana Life Sciences' Shares Rally As Foralumab Shows Encouraging Action In COVID-19 Study In BrazilBenzinga
04:57AM TLSA: COVID-19 Brazilian Study Topline Data ReleasedZacks Small Cap Research
Feb-02-21 04:15AM TLSA: COVID-19 Brazilian Study Topline Data ReleasedZacks Small Cap Research
02:00AM Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in BrazilGlobeNewswire
Jan-27-21 02:00AM Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange CommissionGlobeNewswire
Jan-20-21 06:31AM Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMTGlobeNewswire
02:00AM Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main MarketGlobeNewswire
Jan-13-21 02:00AM Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical OfficerGlobeNewswire
Jan-11-21 12:08PM Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021GlobeNewswire
09:48AM Tiziana Life Sciences to Present at Biotech Showcase Digital 2021GlobeNewswire
Jan-04-21 02:00AM Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in BrazilGlobeNewswire
Dec-18-20 06:38AM Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of ProspectusGlobeNewswire
Dec-17-20 10:04AM Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIMGlobeNewswire
Dec-14-20 10:28AM Could The Tiziana Life Sciences PLC (LON:TILS) Ownership Structure Tell Us Something Useful?Simply Wall St.
Dec-01-20 02:00AM Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ETGlobeNewswire
Nov-18-20 10:16AM Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR DealingGlobeNewswire
Nov-11-20 02:00AM Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s DiseaseGlobeNewswire
Nov-02-20 03:31AM Tiziana Kicks Off Covid-19 Treatment Trial In Brazil; Stock Up 250% YTDSmarterAnalyst
02:00AM Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal AntibodyGlobeNewswire
Oct-27-20 12:00PM Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)GlobeNewswire
Oct-22-20 07:28AM Tiziana Life's (TLSA) Shares March Higher, Can It Continue?Zacks
Oct-02-20 07:00AM Tiziana Life Sciences Plc (the "Company") - Result of General MeetingGlobeNewswire
Sep-25-20 02:00AM Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money ReportGlobeNewswire
Sep-21-20 09:51AM Tiziana Life Sciences plc: Publication of Research NoteGlobeNewswire
Sep-17-20 02:00AM Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in BrazilGlobeNewswire
Sep-16-20 10:10AM Tiziana Life Sciences PLC (LON:TILS) Insiders Increased Their HoldingsSimply Wall St.
06:00AM Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem SciencesGlobeNewswire
Sep-16-20 02:00AM Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in SpecieGlobeNewswire
Aug-28-20 05:30AM Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration StatementGlobeNewswire
Aug-27-20 02:00AM Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive InterviewGlobeNewswire
Aug-24-20 08:42AM Tiziana Wins Patent for Potential Covid-19 TreatmentTheStreet.com
03:14AM Tiziana Wins Patent Approval For TZLS-501 Potential Covid-19 TreatmentSmarterAnalyst
Aug-24-20 02:00AM Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseasesGlobeNewswire
Aug-21-20 02:00AM Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other CancersGlobeNewswire
Aug-20-20 02:00AM Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year TermGlobeNewswire
Aug-18-20 06:08AM Tiziana Spikes 25% In Pre-Market On Patent Win For ForalumabSmarterAnalyst
02:00AM Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s DiseaseGlobeNewswire
Aug-11-20 04:00AM Tiziana Life Sciences to Present at BTIG’s Virtual Biotechnology ConferenceGlobeNewswire
Aug-06-20 03:57AM LD Micro:- Announces Preliminary List of Presenters for the LD 500.ACCESSWIRE
Aug-05-20 11:00AM Tiziana Life Sciences plc Announces Closing of $57.25 Million OfferingGlobeNewswire
Aug-04-20 02:00AM Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 PatientsGlobeNewswire
Aug-03-20 02:00AM Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 millionGlobeNewswire
Jul-31-20 12:05PM Why Tiziana Life Sciences' Stock Is Trading Higher TodayBenzinga
12:00PM Tiziana Life Sciences plc: Total Voting RightsGlobeNewswire
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Cap:    |  Volume (24h):